Health Care

Local EMS Develops DIY EpiPen Alternative for $25

With the continuing controversy over the skyrocketing price of the life-saving EpiPen device, one local EMS developed their own Epi Kit as a cost-saving yet effective alternative. King County EMS James Duren weighed in on how the kit got its start.

Samsung says replacements available for recalled Note 7

Samsung says new Galaxy Note 7 smartphones will be available in U.S. stores starting Wednesday to replace about 1 million devices that are being recalled because of a problem with batteries catching fire.

Feds preview rules of the road for self-driving cars

Obama administration officials previewed long-awaited guidance Monday that attempts to bring self-driving cars to the nation's roadways safely — without creating so many roadblocks that the technology can't make it to market quickly.

GlaxoSmithKline Names Walmsley New CEO

GlaxoSmithKline said on Tuesday it had chosen Emma Walmsley, head of consumer healthcare, as its new chief executive, after considering internal and external candidates.

WebMD CEO Departs By 'Mutual Agreement'

David Schlanger is out as chief executive at WebMD Health Corp., the company said Monday, after a three-year stint leading the health-care advice website.

Insider Q&A: Why so little relief on pricey biologic drugs

Drugs made from living cells, instead of by mixing chemicals, have brought major advances since the late 1990s to the treatment of various cancers, immune system disorders, growth hormone deficiency and eye diseases.

US regulators: Official recall of 1M Samsung Note 7 phones

U.S. safety regulators announced a formal recall of Samsung's Galaxy Note 7 smartphone Thursday after a spate of fires led to injuries and property damage — along with a global marketing headache for the South Korean tech giant.

Oregon settles lawsuit for botched health care rollout

Oregon settled with a California software giant in a lawsuit that accused Oracle America Inc. of collecting tens of millions of dollars to create a state health care exchange website that didn't work.

Bayer-Monsanto's $66B Deal Roils Regulators and Now Politicians

Bayer AG’s $66 billion purchase of Monsanto (NYSE:MON) is facing a nearly unprecedented wall of regulatory and political scrutiny that investors and analysts believe will eventually kill the biggest merger of 2016, the FOX Business Network has learned.